Monotherapy blockade of programmed cell death 1 alone or in combination with other regimens is becoming a popular choice for the treatment of advanced HCC.26 However, to our knowledge, data on the economic outcomes of immune checkpoint inhibitors (ICIs) for the treatment of advanced HCC are scarce. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.